Details of the Drug Combination

General Information of Drug Combination (ID: DCEIUIT)

• Drug Combination Name: Ruxolitinib + Azacitidine
• Indication: Amelanotic melanoma; Status: Investigative [1]
• Component Drugs:
  Ruxolitinib (DM7Q98D): Small molecular drug
  Azacitidine (DMTA5OE): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: MDA-MB-435
  Zero Interaction Potency (ZIP) Score: 6.62
  Bliss Independence Score: 7.87
  Loewe Additivity Score: 1.5
  LHighest Single Agent (HSA) Score: 1.32

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Ruxolitinib

Disease Entry	ICD 11	Status	REF
Essential thrombocythemia	3B63.1Z	Approved	[2]
High-risk myelofibrosis	2A20.2	Approved	[3]
Myelofibrosis	2A22	Approved	[4]
Myeloproliferative neoplasm	2A20	Approved	[5]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[6]
Pancreatic cancer	2C10	Phase 3	[3]
Atopic dermatitis	EA80	Phase 1/2	[7]
Vitiligo	ED63.0	Phase 1/2	[7]

Ruxolitinib Interacts with 5 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Janus kinase 2 (JAK-2)	TTRMX3V	JAK2_HUMAN	Modulator	[10]
Janus kinase 1 (JAK-1)	TT6DM01	JAK1_HUMAN	Modulator	[10]
Urokinase plasminogen activator surface receptor (PLAUR)	TTPRL03	UPAR_HUMAN	Inhibitor	[11]
HUMAN janus kinase 1 (JAK-1)	TTWKB01	JAK1_HUMAN	Inhibitor	[12]
HUMAN janus kinase 2 (JAK-2)	TT0F5HE	JAK2_HUMAN	Inhibitor	[12]

Ruxolitinib Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Mitogen-activated protein kinase 14 (MAPK14)	OT5TCO3O	MK14_HUMAN	Increases ADR	[13]

Indication(s) of Azacitidine

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Approved	[8]
Chronic myelomonocytic leukemia	N.A.	Approved	[8]
Leukemia	N.A.	Approved	[8]
Myelodysplastic syndrome	2A37	Approved	[9]
Myeloproliferative neoplasm	2A20	Approved	[8]
Plasma cell myeloma	2A83.1	Approved	[8]

Azacitidine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA [cytosine-5]-methyltransferase (DNMT)	TTHVCUP	NOUNIPROTAC	Inhibitor	[18]

Azacitidine Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytidine aminohydrolase (CDA)	DEKEDRC	CDD_HUMAN	Metabolism	[19]
Cytidine deaminase (cdd)	DEYILK4	E0TLJ6_MYCHH	Metabolism	[20]

Azacitidine Interacts with 275 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Affects Expression	[21]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Increases Expression	[22]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Increases Expression	[22]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Increases Expression	[22]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Increases Expression	[22]
Sulfotransferase 1C2 (SULT1C2)	OT07MMZS	ST1C2_HUMAN	Increases Expression	[14]
Phospholipid phosphatase 1 (PLPP1)	OT0IIMI5	PLPP1_HUMAN	Increases Expression	[14]
Tectonin beta-propeller repeat-containing protein 2 (TECPR2)	OT1UFECZ	TCPR2_HUMAN	Increases Expression	[14]
TBC1 domain family member 4 (TBC1D4)	OTK66C40	TBCD4_HUMAN	Decreases Expression	[14]
Multiple epidermal growth factor-like domains protein 6 (MEGF6)	OTEUYTP1	MEGF6_HUMAN	Decreases Expression	[14]
Stanniocalcin-2 (STC2)	OT86YP8G	STC2_HUMAN	Decreases Expression	[14]
Integrin beta-2 (ITGB2)	OTEKPEPR	ITB2_HUMAN	Decreases Expression	[14]
Protein S100-A9 (S100A9)	OTOARHCS	S10A9_HUMAN	Increases Expression	[14]
Receptor-type tyrosine-protein phosphatase C (PTPRC)	OT6KOR77	PTPRC_HUMAN	Increases Expression	[14]
Delta-aminolevulinic acid dehydratase (ALAD)	OTHM9GSH	HEM2_HUMAN	Decreases Expression	[14]
Hepatocyte growth factor (HGF)	OTGHUA23	HGF_HUMAN	Increases Expression	[14]
Heat shock 70 kDa protein 6 (HSPA6)	OTH4S7WB	HSP76_HUMAN	Increases Expression	[14]
Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1)	OT4L2SSB	GBRB1_HUMAN	Increases Expression	[14]
Transcription factor E3 (TFE3)	OTM99ZWH	TFE3_HUMAN	Increases Expression	[14]
Pro-thyrotropin-releasing hormone (TRH)	OT02UY2V	TRH_HUMAN	Decreases Expression	[14]
Protein S100-P (S100P)	OTJCXNJG	S100P_HUMAN	Increases Expression	[14]
Protein PML (PML)	OT6SM2GD	PML_HUMAN	Increases Expression	[14]
DNA-binding protein inhibitor ID-1 (ID1)	OTKGNZN5	ID1_HUMAN	Increases Expression	[14]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B)	OTAG24N1	CDN2B_HUMAN	Decreases Methylation	[14]
LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1)	OT729S0T	LIMS1_HUMAN	Increases Expression	[14]
E3 SUMO-protein ligase RanBP2 (RANBP2)	OTFG5CVF	RBP2_HUMAN	Increases Expression	[14]
Cyclin-dependent kinase inhibitor 1C (CDKN1C)	OTASTJ3Q	CDN1C_HUMAN	Increases Expression	[14]
Ras-related protein Rab-13 (RAB13)	OTIQ484I	RAB13_HUMAN	Decreases Methylation	[14]
Lysozyme C (LYZ)	OTD7H0G6	LYSC_HUMAN	Increases Expression	[14]
Claudin-10 (CLDN10)	OT2CVAKY	CLD10_HUMAN	Decreases Expression	[14]
Sushi repeat-containing protein SRPX (SRPX)	OT5B9LXS	SRPX_HUMAN	Decreases Expression	[14]
Protein delta homolog 1 (DLK1)	OTE1VLNB	DLK1_HUMAN	Decreases Methylation	[14]
DNA-binding protein inhibitor ID-3 (ID3)	OTUULW5Z	ID3_HUMAN	Increases Expression	[14]
Collagen alpha-1(XIV) chain (COL14A1)	OTLNJ13O	COEA1_HUMAN	Increases Expression	[14]
Equilibrative nucleoside transporter 2 (SLC29A2)	OTUAOB8T	S29A2_HUMAN	Decreases Expression	[14]
Cytohesin-1 (CYTH1)	OTYH9NRJ	CYH1_HUMAN	Increases Expression	[14]
C3a anaphylatoxin chemotactic receptor (C3AR1)	OT8J0TF8	C3AR_HUMAN	Increases Expression	[14]
DNA dC->dU-editing enzyme APOBEC-3F (APOBEC3F)	OT750IJM	ABC3F_HUMAN	Increases Expression	[14]
Angiogenic factor with G patch and FHA domains 1 (AGGF1)	OTA7U2T8	AGGF1_HUMAN	Increases Expression	[14]
E3 ubiquitin-protein ligase Praja-1 (PJA1)	OTFKTMEI	PJA1_HUMAN	Increases Expression	[14]
Caspase-10 (CASP10)	OTE6J88E	CASPA_HUMAN	Increases Expression	[14]
Tetraspanin-32 (TSPAN32)	OTSXW7EW	TSN32_HUMAN	Decreases Expression	[14]
Tribbles homolog 1 (TRIB1)	OTPEO17G	TRIB1_HUMAN	Decreases Expression	[14]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF)	OTT5JX1F	LITAF_HUMAN	Decreases Expression	[14]
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha (PIP5K1A)	OTVTB5R5	PI51A_HUMAN	Decreases Expression	[14]
Centromere protein O (CENPO)	OTXAH83Y	CENPO_HUMAN	Increases Expression	[14]
Iron-sulfur cluster assembly 1 homolog, mitochondrial (ISCA1)	OTU230MC	ISCA1_HUMAN	Increases Expression	[14]
E3 ubiquitin-protein ligase TRIM8 (TRIM8)	OTS6JFR0	TRIM8_HUMAN	Increases Expression	[14]
Uncharacterized protein C6orf62 (C6ORF62)	OTGK4G35	CF062_HUMAN	Increases Expression	[14]
Metal transporter CNNM2 (CNNM2)	OTZHO8WU	CNNM2_HUMAN	Decreases Expression	[14]
Pantothenate kinase 3 (PANK3)	OT77CFJ6	PANK3_HUMAN	Decreases Expression	[14]
DNA dC->dU-editing enzyme APOBEC-3G (APOBEC3G)	OT410VP5	ABC3G_HUMAN	Increases Expression	[14]
Neuritin (NRN1)	OTWJG0SO	NRN1_HUMAN	Decreases Expression	[14]
NTF2-related export protein 2 (NXT2)	OTK82YVT	NXT2_HUMAN	Increases Expression	[14]
THUMP domain-containing protein 1 (THUMPD1)	OTKU8KWH	THUM1_HUMAN	Increases Expression	[14]
Protein FAM8A1 (FAM8A1)	OT1QVTGS	FA8A1_HUMAN	Increases Expression	[14]
Type 2 lactosamine alpha-2,3-sialyltransferase (ST3GAL6)	OTB17Q43	SIA10_HUMAN	Increases Expression	[14]
Methionine-R-sulfoxide reductase B2, mitochondrial (MSRB2)	OTURGRA8	MSRB2_HUMAN	Increases Expression	[14]
Mitotic spindle assembly checkpoint protein MAD1 (MAD1L1)	OTJCX8K9	MD1L1_HUMAN	Decreases Expression	[14]
Signal-regulatory protein beta-1 (SIRPB1)	OTGHALWJ	SIRB1_HUMAN	Decreases Expression	[15]
Syntenin-1 (SDCBP)	OTS3NCC5	SDCB1_HUMAN	Decreases Expression	[15]
Complexin-1 (CPLX1)	OT7UIGTP	CPLX1_HUMAN	Increases Expression	[15]
Nephrocystin-1 (NPHP1)	OTZHCFFQ	NPHP1_HUMAN	Increases Expression	[15]
Phosphatase and actin regulator 2 (PHACTR2)	OTWMX2A8	PHAR2_HUMAN	Increases Expression	[15]
Nuclear factor of activated T-cells, cytoplasmic 1 (NFATC1)	OT4TMERS	NFAC1_HUMAN	Increases Expression	[15]
Acyl-CoA 6-desaturase (FADS2)	OTUX531P	FADS2_HUMAN	Decreases Expression	[15]
Metalloproteinase inhibitor 1 (TIMP1)	OTOXC51H	TIMP1_HUMAN	Increases Expression	[15]
Cystatin-C (CST3)	OTNZ6AO4	CYTC_HUMAN	Increases Expression	[15]
Cystatin-S (CST4)	OTXXM8EH	CYTS_HUMAN	Increases Expression	[15]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Increases Expression	[15]
Integrin beta-1 (ITGB1)	OT6G1IAR	ITB1_HUMAN	Decreases Expression	[15]
Keratin, type II cytoskeletal 8 (KRT8)	OTTM4X11	K2C8_HUMAN	Increases Expression	[15]
Neurofilament light polypeptide (NEFL)	OTQESJV4	NFL_HUMAN	Increases Expression	[15]
Protein disulfide-isomerase (P4HB)	OTTYNYPF	PDIA1_HUMAN	Increases Expression	[15]
Decorin (DCN)	OTWLJL7K	PGS2_HUMAN	Decreases Expression	[15]
Profilin-1 (PFN1)	OTHTGA1H	PROF1_HUMAN	Increases Expression	[15]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET)	OTLU040A	RET_HUMAN	Decreases Expression	[15]
Tropomyosin beta chain (TPM2)	OTA1L0P8	TPM2_HUMAN	Increases Expression	[15]
Transcription factor Sp1 (SP1)	OTISPT4X	SP1_HUMAN	Decreases Expression	[15]
Keratin, type I cytoskeletal 19 (KRT19)	OTDGDQ75	K1C19_HUMAN	Increases Expression	[15]
Insulin-like growth factor-binding protein 1 (IGFBP1)	OT6UQV2K	IBP1_HUMAN	Increases Expression	[15]
Small ribosomal subunit protein uS2 (RPSA)	OTJZHEGT	RSSA_HUMAN	Decreases Expression	[15]
Glycodelin (PAEP)	OTQA0NV4	PAEP_HUMAN	Decreases Expression	[15]
E3 SUMO-protein ligase EGR2 (EGR2)	OTAVQ78J	EGR2_HUMAN	Increases Expression	[15]
Pregnancy-specific beta-1-glycoprotein 1 (PSG1)	OT1U4ZZW	PSG1_HUMAN	Increases Expression	[15]
Collagen alpha-3(VI) chain (COL6A3)	OTAS6R6I	CO6A3_HUMAN	Decreases Expression	[15]
Parathyroid hormone-related protein (PTHLH)	OTI1JF13	PTHR_HUMAN	Decreases Expression	[15]
Plastin-3 (PLS3)	OTYBM4PK	PLST_HUMAN	Decreases Expression	[15]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2)	OT1LQSGX	MTDC_HUMAN	Decreases Expression	[15]
Pyruvate kinase PKM (PKM)	OTLHHMC2	KPYM_HUMAN	Increases Expression	[15]
Carboxypeptidase E (CPE)	OTXNTV79	CBPE_HUMAN	Increases Expression	[15]
High mobility group protein HMG-I/HMG-Y (HMGA1)	OTQUSHPX	HMGA1_HUMAN	Increases Expression	[15]
Gap junction alpha-1 protein (GJA1)	OTT94MKL	CXA1_HUMAN	Decreases Expression	[15]
Desmin (DES)	OTI09KBW	DESM_HUMAN	Increases Expression	[15]
Plasma membrane calcium-transporting ATPase 1 (ATP2B1)	OT5MXG9W	AT2B1_HUMAN	Decreases Expression	[15]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[15]
5'-nucleotidase (NT5E)	OT7J5LT6	5NTD_HUMAN	Increases Expression	[15]
Fibroblast growth factor 7 (FGF7)	OTGK6ANL	FGF7_HUMAN	Decreases Expression	[15]
Insulin-like growth factor-binding protein 4 (IGFBP4)	OT2HZRBD	IBP4_HUMAN	Increases Expression	[15]
Transcription elongation factor A protein 1 (TCEA1)	OTBFO594	TCEA1_HUMAN	Decreases Expression	[15]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Increases Expression	[15]
Tenascin (TNC)	OTK4FSHR	TENA_HUMAN	Decreases Expression	[15]
V-type proton ATPase 16 kDa proteolipid subunit c (ATP6V0C)	OTKPL09B	VATL_HUMAN	Increases Expression	[15]
Protein ITPRID2 (ITPRID2)	OTO3JDX5	ITPI2_HUMAN	Increases Expression	[15]
Dual specificity protein phosphatase 1 (DUSP1)	OTN6BR75	DUS1_HUMAN	Increases Expression	[15]
Interleukin-12 subunit beta (IL12B)	OT0JF8A3	IL12B_HUMAN	Increases Expression	[15]
Neurotensin/neuromedin N (NTS)	OTPGDNQS	NEUT_HUMAN	Decreases Expression	[15]
Guanylate-binding protein 2 (GBP2)	OTVU4G07	GBP2_HUMAN	Decreases Expression	[15]
MHC class II transactivator (CIITA)	OTRJNZFO	C2TA_HUMAN	Increases Expression	[15]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[15]
Exosome RNA helicase MTR4 (MTREX)	OTSQY30V	MTREX_HUMAN	Increases Expression	[15]
Alpha-S1-casein (CSN1S1)	OTXOW6XJ	CASA1_HUMAN	Increases Expression	[15]
Nuclear receptor-interacting protein 1 (NRIP1)	OTIZOJQV	NRIP1_HUMAN	Decreases Expression	[15]
Homeobox protein Hox-A1 (HOXA1)	OTMSOJ7D	HXA1_HUMAN	Increases Expression	[15]
Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1)	OT6E2OW6	ENTP1_HUMAN	Increases Expression	[15]
Ephrin-A3 (EFNA3)	OTJGOUMZ	EFNA3_HUMAN	Increases Expression	[15]
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1)	OT7FBG5W	NAR1_HUMAN	Increases Expression	[15]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1)	OTYHXLWZ	BCAT1_HUMAN	Decreases Expression	[15]
Microfibrillar-associated protein 2 (MFAP2)	OTMHVBTV	MFAP2_HUMAN	Decreases Expression	[15]
Laminin subunit beta-2 (LAMB2)	OT71OI2Y	LAMB2_HUMAN	Increases Expression	[15]
NHP2-like protein 1 (SNU13)	OTH56TIH	NH2L1_HUMAN	Increases Expression	[15]
Homeobox protein DLX-6 (DLX6)	OT0FIJHY	DLX6_HUMAN	Increases Expression	[15]
Neurotrypsin (PRSS12)	OT1MYL3L	NETR_HUMAN	Decreases Expression	[15]
Elongation factor 1-alpha 1 (EEF1A1)	OT00THXS	EF1A1_HUMAN	Decreases Expression	[15]
Microtubule-associated protein 1A (MAP1A)	OTHO8K43	MAP1A_HUMAN	Decreases Expression	[15]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Expression	[15]
Cytochrome c oxidase subunit 6A2, mitochondrial (COX6A2)	OTQR5SXD	CX6A2_HUMAN	Increases Expression	[15]
cAMP-responsive element modulator (CREM)	OTJIJ5AL	CREM_HUMAN	Decreases Expression	[15]
Caldesmon (CALD1)	OTNJKJ6Q	CALD1_HUMAN	Increases Expression	[15]
ATP-dependent RNA helicase A (DHX9)	OT5AAOQI	DHX9_HUMAN	Decreases Expression	[15]
Serine/threonine-protein kinase PAK 1 (PAK1)	OT17LZNZ	PAK1_HUMAN	Increases Expression	[15]
Dual specificity mitogen-activated protein kinase kinase 5 (MAP2K5)	OT6T408U	MP2K5_HUMAN	Decreases Expression	[15]
Chitotriosidase-1 (CHIT1)	OTPQR0A6	CHIT1_HUMAN	Increases Expression	[15]
Ras and Rab interactor 1 (RIN1)	OTPBROUD	RIN1_HUMAN	Increases Expression	[15]
Keratin, type I cuticular Ha2 (KRT32)	OTZCGZYT	K1H2_HUMAN	Increases Expression	[15]
Semaphorin-3A (SEMA3A)	OTQJSV7W	SEM3A_HUMAN	Increases Expression	[15]
Ras GTPase-activating protein 3 (RASA3)	OT9C54MN	RASA3_HUMAN	Increases Expression	[15]
Mediator of DNA damage checkpoint protein 1 (MDC1)	OTEUQH4J	MDC1_HUMAN	Increases Expression	[15]
Transmembrane glycoprotein NMB (GPNMB)	OTB7KQKV	GPNMB_HUMAN	Decreases Expression	[15]
Mortality factor 4-like protein 2 (MORF4L2)	OT8OI3EC	MO4L2_HUMAN	Decreases Expression	[15]
kinase isozyme 1, mitochondrial (PDK1)	OTMABK9Z	PDK1_HUMAN	Increases Expression	[15]
Serine/threonine-protein kinase 38 (STK38)	OTKMYCYR	STK38_HUMAN	Decreases Expression	[15]
Serine/threonine-protein phosphatase 2A activator (PTPA)	OTRGFOI7	PTPA_HUMAN	Increases Expression	[15]
Reticulocalbin-1 (RCN1)	OT3JBGAG	RCN1_HUMAN	Decreases Expression	[15]
Olfactory receptor 8B8 (OR8B8)	OTCISNYV	OR8B8_HUMAN	Increases Expression	[15]
Leukotriene B4 receptor 1 (LTB4R)	OT3SRH4H	LT4R1_HUMAN	Decreases Expression	[15]
Serine/arginine-rich splicing factor 7 (SRSF7)	OTRS4W4S	SRSF7_HUMAN	Decreases Expression	[15]
Guanylate kinase (GUK1)	OTLI0HRU	KGUA_HUMAN	Increases Expression	[15]
Filamin A-interacting protein 1-like (FILIP1L)	OTPY8IMS	FIL1L_HUMAN	Decreases Expression	[15]
Nucleolar MIF4G domain-containing protein 1 (NOM1)	OTWZSJJC	NOM1_HUMAN	Decreases Expression	[15]
Opioid growth factor receptor-like protein 1 (OGFRL1)	OT6QGBYE	OGRL1_HUMAN	Increases Expression	[15]
Serine/threonine-protein kinase MRCK alpha (CDC42BPA)	OTCPFOSA	MRCKA_HUMAN	Decreases Expression	[15]
Extracellular sulfatase Sulf-1 (SULF1)	OTJCNCO0	SULF1_HUMAN	Decreases Expression	[15]
N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (GCNT2)	OTRUIMC4	GNT2A_HUMAN	Decreases Expression	[15]
Oxidation resistance protein 1 (OXR1)	OTPIDMT3	OXR1_HUMAN	Increases Expression	[15]
Alpha-2,8-sialyltransferase 8B (ST8SIA2)	OTRBBBD8	SIA8B_HUMAN	Decreases Expression	[15]
Type II iodothyronine deiodinase (DIO2)	OTGPNSLH	IOD2_HUMAN	Decreases Expression	[15]
G-patch domain and KOW motifs-containing protein (GPKOW)	OTGS3H0M	GPKOW_HUMAN	Increases Expression	[15]
Rho guanine nucleotide exchange factor 2 (ARHGEF2)	OTBQTFRT	ARHG2_HUMAN	Decreases Expression	[15]
Homogentisate 1,2-dioxygenase (HGD)	OTTKLQOO	HGD_HUMAN	Increases Expression	[15]
Secretory carrier-associated membrane protein 4 (SCAMP4)	OTSCZTJ5	SCAM4_HUMAN	Increases Expression	[15]
Protein bicaudal D homolog 1 (BICD1)	OT78IYPF	BICD1_HUMAN	Decreases Expression	[15]
Ankyrin repeat and SOCS box protein 2 (ASB2)	OTF9LV7L	ASB2_HUMAN	Increases Expression	[15]
Eyes absent homolog 1 (EYA1)	OTHU807A	EYA1_HUMAN	Decreases Expression	[15]
Bcl-2-like protein 13 (BCL2L13)	OT2VRFTM	B2L13_HUMAN	Increases Expression	[15]
RNA helicase Mov10l1 (MOV10L1)	OTP978LK	M10L1_HUMAN	Increases Expression	[15]
Rac GTPase-activating protein 1 (RACGAP1)	OTQE8IEH	RGAP1_HUMAN	Increases Expression	[15]
Ras-related protein Rab-1B (RAB1B)	OTAFCUAS	RAB1B_HUMAN	Increases Expression	[15]
Semaphorin-6C (SEMA6C)	OT1N59T5	SEM6C_HUMAN	Increases Expression	[15]
Sentrin-specific protease 3 (SENP3)	OTFQDOMC	SENP3_HUMAN	Increases Expression	[15]
Ribonuclease P protein subunit p21 (RPP21)	OT53MDNE	RPP21_HUMAN	Increases Expression	[15]
Protocadherin-18 (PCDH18)	OTTLQWRN	PCD18_HUMAN	Decreases Expression	[15]
Protein S100-A14 (S100A14)	OTVFJJ91	S10AE_HUMAN	Decreases Expression	[15]
Tryptase gamma (TPSG1)	OTDESHKT	TRYG1_HUMAN	Decreases Expression	[15]
Rho GTPase-activating protein 35 (ARHGAP35)	OTJ8POG0	RHG35_HUMAN	Increases Expression	[15]
Neuroligin-3 (NLGN3)	OTKDEC1Q	NLGN3_HUMAN	Increases Expression	[15]
Polycystin-2-like protein 1 (PKD2L1)	OT1KJDAT	PK2L1_HUMAN	Increases Expression	[15]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1)	OTTLJH8W	ATS1_HUMAN	Decreases Expression	[15]
Cytoplasmic phosphatidylinositol transfer protein 1 (PITPNC1)	OT64TTGC	PITC1_HUMAN	Decreases Expression	[15]
Transcription factor SOX-13 (SOX13)	OTCIF6KC	SOX13_HUMAN	Decreases Expression	[15]
Afadin- and alpha-actinin-binding protein (SSX2IP)	OTEIZ7N1	ADIP_HUMAN	Increases Expression	[15]
Transmembrane emp24 domain-containing protein 3 (TMED3)	OTNOPHHC	TMED3_HUMAN	Increases Expression	[15]
Protocadherin beta-4 (PCDHB4)	OTF665E0	PCDB4_HUMAN	Decreases Expression	[15]
Protocadherin beta-14 (PCDHB14)	OTFZF1ST	PCDBE_HUMAN	Decreases Expression	[15]
Adenylate kinase isoenzyme 5 (AK5)	OTTGXLOT	KAD5_HUMAN	Increases Expression	[15]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Increases Expression	[23]
Alpha-fetoprotein (AFP)	OT9GG3ZI	FETA_HUMAN	Increases Expression	[23]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[23]
Tyrosine aminotransferase (TAT)	OT2CJ91O	ATTY_HUMAN	Increases Expression	[23]
Hepatocyte nuclear factor 4-alpha (HNF4A)	OTY1TOAB	HNF4A_HUMAN	Increases Expression	[23]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Increases Expression	[23]
Hematopoietically-expressed homeobox protein HHEX (HHEX)	OTLIUVYX	HHEX_HUMAN	Increases Expression	[23]
Suppressor of cytokine signaling 3 (SOCS3)	OTY183WJ	SOCS3_HUMAN	Affects Expression	[21]
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Decreases Expression	[24]
Aquaporin-9 (AQP9)	OTLGH5ZY	AQP9_HUMAN	Increases Expression	[25]
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 (GNG7)	OTHS1L0E	GBG7_HUMAN	Affects Methylation	[26]
Claudin-7 (CLDN7)	OTNE0XHQ	CLD7_HUMAN	Decreases Expression	[27]
Claudin-9 (CLDN9)	OTCKI2IZ	CLD9_HUMAN	Increases Expression	[28]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[24]
Calcitonin (CALCA)	OTZ11LHB	CALC_HUMAN	Decreases Methylation	[29]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Increases Response To Substance	[30]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Increases Expression	[31]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Affects Activity	[32]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Affects Methylation	[33]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Affects Methylation	[33]
Tyrosine-protein kinase Fyn (FYN)	OTLSLVZS	FYN_HUMAN	Increases Expression	[34]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Increases Expression	[35]
L-lactate dehydrogenase B chain (LDHB)	OT9B1CT3	LDHB_HUMAN	Increases Expression	[36]
Thyroid peroxidase (TPO)	OTJJLL20	PERT_HUMAN	Increases Expression	[37]
Prostate-specific antigen (KLK3)	OTFGSBFJ	KLK3_HUMAN	Increases Expression	[35]
Histone H1.0 (H1-0)	OTRLJK4Z	H10_HUMAN	Increases Expression	[38]
Interleukin-6 receptor subunit alpha (IL6R)	OTCQL07Z	IL6RA_HUMAN	Affects Expression	[21]
Gamma-enolase (ENO2)	OTRODL0T	ENOG_HUMAN	Decreases Expression	[39]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Increases Expression	[35]
Microtubule-associated protein tau (MAPT)	OTMTP2Z7	TAU_HUMAN	Decreases Expression	[40]
Chromogranin-A (CHGA)	OTXYX5JH	CMGA_HUMAN	Decreases Expression	[39]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Decreases Expression	[35]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Increases Expression	[41]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Increases Expression	[39]
15-hydroxyprostaglandin dehydrogenase (HPGD)	OTYZI6JB	PGDH_HUMAN	Decreases Methylation	[42]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[43]
Methylated-DNA--protein-cysteine methyltransferase (MGMT)	OT40A9WH	MGMT_HUMAN	Increases Expression	[44]
Thyrotropin receptor (TSHR)	OT0BC8LB	TSHR_HUMAN	Increases Expression	[37]
Hepatocyte nuclear factor 1-alpha (HNF1A)	OT9DOUKL	HNF1A_HUMAN	Increases Expression	[25]
Fibulin-1 (FBLN1)	OT5MHHOP	FBLN1_HUMAN	Increases Expression	[34]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[45]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Expression	[35]
DNA cytosine-5)-methyltransferase 1 (DNMT1)	OTM2DGTK	DNMT1_HUMAN	Decreases Expression	[46]
G1/S-specific cyclin-D2 (CCND2)	OTDULQF9	CCND2_HUMAN	Affects Methylation	[47]
Oxytocin receptor (OXTR)	OT7WFW4U	OXYR_HUMAN	Decreases Expression	[34]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Affects Expression	[21]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Decreases Methylation	[48]
Melanoma-associated antigen 1 (MAGEA1)	OTXAO193	MAGA1_HUMAN	Decreases Methylation	[48]
Melanoma-associated antigen 3 (MAGEA3)	OTW3Y5M4	MAGA3_HUMAN	Increases Expression	[49]
Killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1)	OTL1LBQJ	KI2L1_HUMAN	Increases Expression	[50]
Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2)	OTOVUTJD	KI2L2_HUMAN	Increases Expression	[50]
Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3)	OTFCN53B	KI2L3_HUMAN	Increases Expression	[50]
Killer cell immunoglobulin-like receptor 3DL1 (KIR3DL1)	OTPOSXFX	KI3L1_HUMAN	Increases Expression	[50]
Killer cell immunoglobulin-like receptor 2DS4 (KIR2DS4)	OT00N6UJ	KI2S4_HUMAN	Increases Expression	[50]
Tumor necrosis factor ligand superfamily member 6 (FASLG)	OTZARCHH	TNFL6_HUMAN	Increases Response To Substance	[30]
Stromal cell-derived factor 1 (CXCL12)	OT2QX5LL	SDF1_HUMAN	Increases Expression	[51]
Tuberin (TSC2)	OT47LWI9	TSC2_HUMAN	Increases Expression	[52]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)	OT4PXBTA	TNF10_HUMAN	Increases Response To Substance	[30]
High mobility group protein HMGI-C (HMGA2)	OTBMBHHL	HMGA2_HUMAN	Increases Expression	[34]
Homeobox protein Nkx-2.5 (NKX2-5)	OTS1SAWM	NKX25_HUMAN	Increases Expression	[53]
Death-associated protein kinase 1 (DAPK1)	OTNCNUCO	DAPK1_HUMAN	Affects Methylation	[54]
Claudin-6 (CLDN6)	OTEN8ID2	CLD6_HUMAN	Increases Expression	[28]
Claudin-8 (CLDN8)	OT7IIWXG	CLD8_HUMAN	Increases Expression	[28]
Small ribosomal subunit protein eS6 (RPS6)	OTT4D1LN	RS6_HUMAN	Decreases Phosphorylation	[34]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA)	OT83PT85	PP2AA_HUMAN	Increases Expression	[55]
Cyclin-A1 (CCNA1)	OTX4HD45	CCNA1_HUMAN	Decreases Expression	[56]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Decreases Activity	[57]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Affects Localization	[21]
Tight junction protein ZO-1 (TJP1)	OTBDCUPK	ZO1_HUMAN	Increases Expression	[28]
Dihydropyrimidine dehydrogenase (DPYD)	OTWRF2NR	DPYD_HUMAN	Decreases Methylation	[58]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)	OT4SO7J4	BNIP3_HUMAN	Increases Expression	[59]
N-myc-interactor (NMI)	OTYVG3NM	NMI_HUMAN	Increases Expression	[34]
NAD(P) transhydrogenase, mitochondrial (NNT)	OTAIOGZK	NNTM_HUMAN	Increases Expression	[27]
Runt-related transcription factor 3 (RUNX3)	OTITK1XD	RUNX3_HUMAN	Affects Methylation	[60]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Expression	[61]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Decreases Expression	[34]
Occludin (OCLN)	OTSUTVWL	OCLN_HUMAN	Increases Expression	[28]
kinase isozyme 4, mitochondrial (PDK4)	OTCMHMBZ	PDK4_HUMAN	Decreases Methylation	[62]
Dual specificity protein phosphatase 6 (DUSP6)	OT4H6RKW	DUS6_HUMAN	Increases Expression	[34]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B)	OTE8GBUR	RIR2B_HUMAN	Increases Expression	[63]
Sodium/iodide cotransporter (SLC5A5)	OTU7E9G7	SC5A5_HUMAN	Increases Expression	[64]
Krueppel-like factor 6 (KLF6)	OTQY9S7F	KLF6_HUMAN	Increases Expression	[34]
Killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4)	OTXN18OA	KI2L4_HUMAN	Increases Expression	[50]
Protein Niban 1 (NIBAN1)	OTYOLI12	NIBA1_HUMAN	Increases Expression	[34]
Calcium homeostasis modulator protein 2 (CALHM2)	OTWWM6HI	CAHM2_HUMAN	Increases Expression	[27]
Homeobox protein SIX2 (SIX2)	OTYOVGSC	SIX2_HUMAN	Decreases Expression	[27]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1)	OT9HYT7A	PLCB1_HUMAN	Increases Expression	[65]
Sal-like protein 4 (SALL4)	OTC08PR5	SALL4_HUMAN	Affects Methylation	[17]
Transcription factor MafB (MAFB)	OTH2N3T8	MAFB_HUMAN	Increases Expression	[27]
Sodium/nucleoside cotransporter 1 (SLC28A1)	OTXWVV9O	S28A1_HUMAN	Increases Response To Substance	[66]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable	DCAW80U	N. A.	Phase 1	[67]
Adult T acute lymphoblastic leukemia	DCY451E	MOLT-4	Investigative	[68]
Clear cell renal cell carcinoma	DC25N58	A498	Investigative	[68]
Invasive ductal carcinoma	DCUQ9XJ	T-47D	Investigative	[69]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Ruxolitinib FDA Label
• [6] Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Azacitidine FDA Label
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6796).
• [10] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [11] Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69.
• [12] The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
• [13] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [14] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [15] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [16] Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur J Haematol. 2009 Mar;82(3):176-83. doi: 10.1111/j.1600-0609.2008.01189.x. Epub 2008 Dec 5.
• [17] Novel approach for detecting global epigenetic alterations associated with tumor cell aneuploidy. Int J Cancer. 2007 Oct 1;121(7):1487-93. doi: 10.1002/ijc.22847.
• [18] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
• [19] A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4.
• [20] Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
• [21] The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica. 2008 Jun;93(6):860-9. doi: 10.3324/haematol.12261. Epub 2008 Apr 28.
• [22] Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. Toxicol Lett. 2003 Sep 30;144(2):247-56.
• [23] Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. Arch Toxicol. 2017 Apr;91(4):1815-1832.
• [24] Alpha anomer of 5-aza-2'-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells. Biochem Pharmacol. 2008 Feb 15;75(4):965-72. doi: 10.1016/j.bcp.2007.10.018. Epub 2007 Oct 22.
• [25] Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. J Hematol Oncol. 2015 May 8;8:46. doi: 10.1186/s13045-015-0143-3.
• [26] Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer. Br J Cancer. 2008 Jan 29;98(2):410-7. doi: 10.1038/sj.bjc.6604124. Epub 2008 Jan 22.
• [27] CRISPR-based DNA methylation editing of NNT rescues the cisplatin resistance of lung cancer cells by reducing autophagy. Arch Toxicol. 2023 Feb;97(2):441-456. doi: 10.1007/s00204-022-03404-0. Epub 2022 Nov 6.
• [28] Prevention of murine experimental corneal trauma by epigenetic events regulating claudin 6 and claudin 9. Jpn J Ophthalmol. 2008 May-Jun;52(3):195-203. doi: 10.1007/s10384-008-0524-z. Epub 2008 Jul 27.
• [29] Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693.
• [30] Sensitization by 5-azacytidine toward death receptor-induced hepatic apoptosis. J Pharmacol Exp Ther. 2009 Jan;328(1):107-15. doi: 10.1124/jpet.108.143560. Epub 2008 Sep 30.
• [31] Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
• [32] Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
• [33] Hypomethylation of interleukin-4 and -6 promoters in T cells from systemic lupus erythematosus patients. Acta Pharmacol Sin. 2008 Jan;29(1):105-12. doi: 10.1111/j.1745-7254.2008.00739.x.
• [34] Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2076-81. doi: 10.1073/pnas.1011936108. Epub 2011 Jan 18.
• [35] Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.
• [36] Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS One. 2013;8(2):e57697. doi: 10.1371/journal.pone.0057697. Epub 2013 Feb 21.
• [37] The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake. Cancer Biother Radiopharm. 2007 Jun;22(3):443-9. doi: 10.1089/cbr.2006.319.A.
• [38] Characterisation of human histone H1x. Biol Chem. 2005 Jun;386(6):541-51. doi: 10.1515/BC.2005.064.
• [39] Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Exp Med. 2010 Mar 28;3(2):95-102.
• [40] Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
• [41] Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer. 2007 Jul 1;110(1):87-95. doi: 10.1002/cncr.22758.
• [42] 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res. 2009 Jul 15;15(14):4572-80. doi: 10.1158/1078-0432.CCR-08-2518. Epub 2009 Jul 7.
• [43] DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752-71. doi: 10.1128/MCB.01799-07. Epub 2007 Nov 8.
• [44] CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis. 2003 Aug;24(8):1337-45. doi: 10.1093/carcin/bgg086. Epub 2003 May 22.
• [45] Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 2009 Feb 15;69(4):1527-35. doi: 10.1158/0008-5472.CAN-08-3609. Epub 2009 Feb 3.
• [46] The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/?catenin pathway and DNA methyltransferase-1. Oncol Rep. 2017 Nov;38(5):3114-3120. doi: 10.3892/or.2017.5945. Epub 2017 Sep 7.
• [47] Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl). 2006 Nov;84(11):911-8. doi: 10.1007/s00109-006-0099-4. Epub 2006 Sep 22.
• [48] Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol. 2007 Sep;138(5):616-23. doi: 10.1111/j.1365-2141.2007.06707.x.
• [49] Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy. 2011 May;13(5):618-28. doi: 10.3109/14653249.2010.529893. Epub 2010 Dec 20.
• [50] DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol. 2009 Feb;130(2):213-24. doi: 10.1016/j.clim.2008.08.009. Epub 2008 Oct 22.
• [51] Tamoxifen epigenetically modulates CXCL12 expression in MCF-7 breast cancer cells. Biomed Pharmacother. 2010 Jan;64(1):54-7. doi: 10.1016/j.biopha.2009.04.041. Epub 2009 Sep 2.
• [52] Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res. 2009 Jul;33(7):891-7. doi: 10.1016/j.leukres.2009.01.041. Epub 2009 Feb 27.
• [53] 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang. 2008 Aug;95(2):137-48. doi: 10.1111/j.1423-0410.2008.01076.x. Epub 2008 Jun 28.
• [54] Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol. 2007 Jun;60(6):664-9. doi: 10.1136/jcp.2006.038331.
• [55] Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J Immunol. 2009 Feb 1;182(3):1500-8. doi: 10.4049/jimmunol.182.3.1500.
• [56] Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood. 2007 Nov 15;110(10):3648-55. doi: 10.1182/blood-2007-06-096701. Epub 2007 Aug 13.
• [57] A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
• [58] Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res. 2004 Oct 15;10(20):7100-7. doi: 10.1158/1078-0432.CCR-04-0337.
• [59] Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine. Eur J Cancer. 2014 Dec;50(18):3243-61. doi: 10.1016/j.ejca.2014.09.012. Epub 2014 Oct 13.
• [60] Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest. 2007 Dec;25(8):685-90. doi: 10.1080/07357900701561131.
• [61] [5-azacytidine enhances anti-tumor efficacy of doxorubicin to neuroblastoma cell lines]. Zhongguo Dang Dai Er Ke Za Zhi. 2007 Dec;9(6):577-9.
• [62] Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins. Mol Pharmacol. 2017 Mar;91(3):189-196. doi: 10.1124/mol.116.106757. Epub 2016 Dec 21.
• [63] p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008 Nov 15;68(22):9358-66. doi: 10.1158/0008-5472.CAN-08-1860.
• [64] Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006 Sep;13(3):797-826. doi: 10.1677/erc.1.01143.
• [65] Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16811-6. doi: 10.1073/pnas.0907109106. Epub 2009 Sep 10.
• [66] Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther. 2009 Jan;8(1):225-31. doi: 10.1158/1535-7163.MCT-08-0743.
• [67] ClinicalTrials.gov (NCT01787487) Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
• [68] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [69] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.